Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5905511 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7255955 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3353601 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL6101124 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL6099403 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13127870 | 0.88 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8783095 | 0.86 | MEN1 (0.49) | — | |
| SCHEMBL2877540 | 0.86 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9137609 | 0.86 | MEN1 (0.49) | — | |
| SCHEMBL2877536 | 0.86 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | US | claimed |
| EP-2773637-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| EP-1931341-B1 | 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS | SERVIER LAB (FR) | 2009-11-04 | — | — | EP | disclosed |
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | HTR5A, HTR6, HTR2B | SLC6A2 44/4885SLC6A4 22/4885SLC6A3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.